Vincristine Treatment Protects Against Podocyte Damage in Focal Segmental Glomerulosclerosis

William J. Mason(Great Ormond Street Hospital), Ruth J. Pepper(University College Hospital), Alice Gage(University College Hospital), Stefano Da Sacco(University of Southern California), Laura Perin(University of Southern California), Marilina Antonelou(The Royal Free Hospital), Gideon Pomeranz(Great Ormond Street Hospital), David A. Long(Great Ormond Street Hospital), Jennifer C. Chandler(Great Ormond Street Hospital), Scott R Henderson(The Royal Free Hospital), Karen Price(Eli Lilly (United States)), Alan D. Salama(The Royal Free Hospital)
Kidney International Reports
August 15, 2025
10.1016/j.ekir.2025.08.002
Cited by 3

Related Papers

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier
|Nature Communications|2019|225
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
|JAMA|2021|208
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156
IL-10 Suppresses Chemokines, Inflammation, and Fibrosis in a Model of Chronic Renal Disease
|Journal of the American Society of Nephrology|2005|154